ADVFN Logo
Boards:
    Quotes:
      Boards
      News
      Market Data
      Markets
      Discover
      Subscribe Login/Register Profile Icon
      S&P 500
      5,631.22
      0.28%
      US Tech 100
      19,884.80
      0.46%
      Dow Jones
      40,211.72
      0.53%
      Brent Oil
      83.845
      -0.59%
      Bitcoin
      63,748.98
      -1.70%
      Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.
      Get Started
      1. Home
      2. Investing
      3. Stocks
      4. USA
      5. NASDAQ

      6. Relay Therapeutics Inc (RLAY) Quote

      Relay Therapeutics Inc

      Relay Therapeutics Inc (RLAY)

      NASDAQ
      8.27
      0.03
      (0.36%)
      Closed July 16 4:00PM
      Delayed by 15 minutes
      8.27
      0.00
      (0.00%)
      After Hours: 7:59PM
      Delayed by 15 minutes

      Professional-Grade Tools, for Individual Investors.

      Premium

      Key stats and details

      Current Price
      8.27
      Bid
      7.40
      Ask
      8.55
      Volume
      1,363,914
      8.074 Day's Range 8.52
      5.70 52 Week Range 13.30
      Market Cap
      1.094B
      Previous Close
      8.24
      Open
      8.28
      Last Trade
      8700
      @
      8.27
      (priorref)
      Last Trade Time
      Financial Volume
      $ 11,331,305
      VWAP
      8.3079
      Average Volume (3m)
      1,298,006
      Shares Outstanding
      132,741,677
      Dividend Yield
      -
      PE Ratio
      -3.21
      Earnings Per Share (EPS)
      -2.58
      Revenue
      31.97M
      Net Profit
      -341.97M

      About Relay Therapeutics Inc

      Relay Therapeutics Inc is a clinical-stage, precision medicines company transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology. The company is advancing its pipeline of medicines to address targets in precision oncology, i... Relay Therapeutics Inc is a clinical-stage, precision medicines company transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology. The company is advancing its pipeline of medicines to address targets in precision oncology, including its lead product candidates, RLY-4008 and RLY-1971, as well as its PI3Ka mutant selective program, known as the RLY-PI3K1047 program. Its initiated a Phase 1 clinical trial for RLY-1971 in patients with advanced solid tumors in the first quarter of 2020 and a first-in-human clinical trial of RLY-4008 enriched for patients with advanced solid tumors having oncogenic FGFR2 alterations in the third quarter of 2020. Show more

      Sector
      Biological Pds,ex Diagnstics
      Industry
      Biological Pds,ex Diagnstics
      Website
      www.relaytx.com
      Headquarters
      Wilmington, Delaware, USA
      Founded
      1970
      Relay Therapeutics Inc is listed in the Biological Pds,ex Diagnstics sector of the NASDAQ with ticker RLAY. The last closing price for Relay Therapeutics was $8.24. Over the last year, Relay Therapeutics shares have traded in a share price range of $ 5.70 to $ 13.30.

      Relay Therapeutics currently has 132,741,677 shares outstanding. The market capitalization of Relay Therapeutics is $1.09 billion. Relay Therapeutics has a price to earnings ratio (PE ratio) of -3.21.

      RLAY Latest News

      More News

      Form 4 - Statement of changes in beneficial ownership of securities

      June 12 2024
      Edgar (US Regulatory)

      Form 8-K - Current report

      June 06 2024
      Edgar (US Regulatory)

      Relay Therapeutics Discloses Three New Programs at New Program & Platform Event

      3 new programs include 2 genetic disease programs – vascular malformations & Fabry disease – & 1 precision oncology program – NRAS-specific inhibitor Cash guidance remains unchanged, and...

      June 06 2024
      GlobeNewswire Inc.

      Form 4 - Statement of changes in beneficial ownership of securities

      June 05 2024
      Edgar (US Regulatory)

      Form 4 - Statement of changes in beneficial ownership of securities

      June 05 2024
      Edgar (US Regulatory)

      Form 4 - Statement of changes in beneficial ownership of securities

      June 05 2024
      Edgar (US Regulatory)

      Form 4 - Statement of changes in beneficial ownership of securities

      June 05 2024
      Edgar (US Regulatory)

      Form 144 - Report of proposed sale of securities

      June 05 2024
      Edgar (US Regulatory)
      PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
      11.7827.42681047776.498.526.3610758337.4935343CS
      40.9713.28767123297.38.525.95513404736.88564074CS
      122.2537.37541528246.028.715.712980066.86898128CS
      26-2.55-23.567467652510.8211.165.712348977.80434052CS
      52-4.03-32.764227642312.313.35.711475508.5087268CS
      156-24.86-75.037730153933.1338.155.7107763416.29898944CS
      260-25.71-75.662154208433.9864.375.794089119.59990659CS

      Movers

      View all
      • Most Active
      • % Gainers
      • % Losers
      SymbolPriceVol.
      AMIXAutonomix Medical Inc
      $ 1.3701
      (121.70%)
      		154.81M
      SHOTWSafety Shot Inc
      $ 0.41
      (115.79%)
      		7.56k
      DATSDatChat Inc
      $ 1.89
      (81.73%)
      		54.75M
      CYNCYNGN Inc
      $ 9.18
      (53.77%)
      		17.79M
      SCNIScinai Immunotherapeutics Ltd
      $ 5.80
      (42.86%)
      		29.37M
      ASLNASLAN Pharmaceuticals Ltd
      $ 1.36
      (-46.67%)
      		1.16M
      KZIAKazia Therapeutics Ltd
      $ 0.5593
      (-37.56%)
      		15.34M
      LCFYLocafy Ltd
      $ 3.5597
      (-36.32%)
      		584.38k
      NAASNaaS Technology Inc
      $ 2.82
      (-33.02%)
      		1.94M
      ZENVZenvia Inc
      $ 1.67
      (-26.75%)
      		658.26k
      FFIEFaraday Future Intelligent Electric Inc
      $ 0.5152
      (22.09%)
      		217.92M
      NVDANVIDIA Corporation
      $ 128.44
      (-0.62%)
      		208.32M
      SQQQProShares UltraPro Short QQQ
      $ 7.46
      (-0.67%)
      		155.14M
      AMIXAutonomix Medical Inc
      $ 1.3701
      (121.70%)
      		154.81M
      TSLATesla Inc
      $ 252.64
      (1.78%)
      		147.31M

      RLAY Discussion

      View Posts
      Monksdream Monksdream 4 months ago
      RLAY under $10
      👍️0
      Monksdream Monksdream 1 year ago
      Using AI to find the next blockbuster drug
      This week, AI chipmaker Nvidia placed their bet — investing $50M into AI drug discovery platform Recursion Pharmaceuticals (NASDAQ:RXRX) — sending its stock up 78%.



      Drugmakers are already benefiting from using AI to discover new drugs. And in the process, AI is speeding up and reducing the cost of the long and expensive drug development process.
      Between 2015 and 2022, the cumulative investment in AI drug development has risen from under $1B to $24.6B.
      In the next decade, Morgan Stanley expects AI will help develop an additional 50 drugs with an extra $50B in sales.
      Following Nvidia’s investment, other AI drug discovery platforms rose on the news, including Exscientia (NASDAQ:EXAI), AbCellera Biologics (NASDAQ:ABCL) and Relay Therapeutics (NASDAQ:RLAY).
      Recursion has five drugs, and Exscientia has three drugs discovered with AI, which are already in human trials. And within the startup sector, AI drug discovery has quickly become one of the hottest markets for investment.
      👍️0

      Your Recent History

      NASDAQ
      RLAY
      Relay Therapeutics
      Delayed Upgrade Clock